Rosetta Genomics Ltd. (ROSGQ)

Market Cap	1.19K -99.8%
Revenue (ttm)	2.86M +106.4%
Net Income	-13.39M
EPS	-6.41
Shares Out	5.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,018
Average Volume	4,535
Open	0.0001
Previous Close	0.0000
Day's Range	0.0001 - 0.0002
52-Week Range	0.0000 - 0.0002
Beta	75.48
RSI	63.72
Earnings Date	n/a

About Rosetta Genomics

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 86
• Stock Exchange: OTCMKTS
• Ticker Symbol: ROSGQ

Financial Performance

In 2016, Rosetta Genomics's revenue was $2.04 million, a decrease of -29.08% compared to the previous year's $2.88 million. Losses were -$16.23 million, -6.41% less than in 2015.